Genmab CEO is “the happiest man in the world”
Genmab’s CEO, Jan van de Winkel, is all cheers following the approval of daratumumab, which could herald a new stage in the biotech company’s development if sales turn out as expected. He describes as the “most important milestone in the history of the company.”
BY NIKLAS KRIGSLUND
When the US authorities this week green-lighted Genmab’s cancer drug daratumumab, it was not only good news for patients suffering from bone marrov cancer.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Genmab outlines royalty deal with Janssen
For abonnenter
Genmab has bagged USD 170 million in milestones
For abonnenter
Genmab earns million-dollar milestone payment
For abonnenter
